Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Evaluation of Potential Drug-Drug Interaction Between Delayed-Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women.

Zhu B, Nestorov I, Zhao G, Meka V, Leahy M, Kam J, Sheikh SI.

Clin Pharmacol Drug Dev. 2017 Nov;6(6):604-613. doi: 10.1002/cpdd.377. Epub 2017 Aug 7.

2.

Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol.

Song IH, Borland J, Chen S, Wajima T, Peppercorn AF, Piscitelli SC.

Ann Pharmacother. 2015 Jul;49(7):784-9. doi: 10.1177/1060028015580637. Epub 2015 Apr 10.

3.

A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.

Gruber D, Skřivánek A, Serrani M, Lanius V, Merz M.

Contraception. 2015 Feb;91(2):105-12. doi: 10.1016/j.contraception.2014.10.003. Epub 2014 Oct 13.

PMID:
25453582
4.

Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive.

Hofmann B, Reinecke I, Schuett B, Merz M, Zurth C.

Int J Clin Pharmacol Ther. 2014 Dec;52(12):1059-70. doi: 10.5414/CP202064.

5.

Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.

Bifano M, Sevinsky H, Hwang C, Kandoussi H, Jiang H, Grasela D, Bertz R.

Antivir Ther. 2014;19(5):511-9. doi: 10.3851/IMP2718. Epub 2013 Dec 17.

PMID:
24343001
6.

Antimüllerian hormone levels decrease in women using combined contraception independently of administration route.

Kallio S, Puurunen J, Ruokonen A, Vaskivuo T, Piltonen T, Tapanainen JS.

Fertil Steril. 2013 Apr;99(5):1305-10. doi: 10.1016/j.fertnstert.2012.11.034. Epub 2012 Dec 20.

PMID:
23260855
7.

Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women.

Upreti VV, Hsiang CB, Li L, Xu X, LaCreta FP, Boulton DW.

Diabetes Obes Metab. 2012 Dec;14(12):1155-7. doi: 10.1111/j.1463-1326.2012.01635.x. Epub 2012 Jul 9.

PMID:
22776778
8.

Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.

Anderson MS, Hanley WD, Moreau AR, Jin B, Bieberdorf FA, Kost JT, Wenning LA, Stone JA, Wagner JA, Iwamoto M.

Br J Clin Pharmacol. 2011 Apr;71(4):616-20. doi: 10.1111/j.1365-2125.2010.03885.x.

9.

High levels of women's satisfaction and compliance with transdermal contraception: results from a European multinational, 6-month study.

Jakimiuk AJ, Crosignani PG, Chernev T, Prilepskaya V, Bergmans P, Von Poncet M, Marelli S, Lee EJ.

Gynecol Endocrinol. 2011 Oct;27(10):849-56. doi: 10.3109/09513590.2010.538095. Epub 2010 Dec 10.

10.

[Combined hormonal contraception in cycles artificially extended].

Bustillos-Alamilla E, Zepeda-Zaragoza J, Hernández-Ruiz MA, Briones-Landa CH.

Ginecol Obstet Mex. 2010 Jan;78(1):37-45. Spanish.

PMID:
20931801
11.

Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.

Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, Klingman KL, Cohn SE.

J Acquir Immune Defic Syndr. 2010 Dec;55(4):473-82. doi: 10.1097/QAI.0b013e3181eb5ff5.

12.

Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study.

Massaro M, Di Carlo C, Gargano V, Formisano C, Bifulco G, Nappi C.

Contraception. 2010 Mar;81(3):209-14. doi: 10.1016/j.contraception.2009.09.011. Epub 2009 Oct 29.

PMID:
20159176
13.

Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.

Schwartz JI, Liu F, Wang YH, Pramanik B, Johnson-Levonas AO, Gutierrez MJ, Lai E, Wagner JA.

Am J Ther. 2009 Nov-Dec;16(6):487-95. doi: 10.1097/MJT.0b013e3181985130.

PMID:
19940609
14.

Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy.

Crosignani PG, Nappi C, Ronsini S, Bruni V, Marelli S, Sonnino D; Italian EVRA Contrast Study Group.

BMC Womens Health. 2009 Jun 30;9:18. doi: 10.1186/1472-6874-9-18.

15.

Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis.

Vercellini P, Barbara G, Somigliana E, Bianchi S, Abbiati A, Fedele L.

Fertil Steril. 2010 May 1;93(7):2150-61. doi: 10.1016/j.fertnstert.2009.01.071. Epub 2009 Mar 27.

PMID:
19328469
16.

Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.

Schwartz JI, Dunbar S, Yuan J, Li S, Miller DL, Rosko K, Johnson-Levonas AO, Lasseter KC, Wagner JA.

J Clin Pharmacol. 2009 Jan;49(1):72-9. doi: 10.1177/0091270008325930. Epub 2008 Oct 20.

PMID:
18936284
17.

Effect of the ethinylestradiol/norelgestromin contraceptive patch on body composition. Results of bioelectrical impedance analysis in a population of Italian women.

Piccoli A, Crosignani P, Nappi C, Ronsini S, Bruni V, Marelli S; Italian EVRA Contrast Study Group.

Nutr J. 2008 Aug 26;7:21. doi: 10.1186/1475-2891-7-21.

18.

A clinical study of transdermal contraceptive patch in Thai adolescence women.

Piyasirisilp R, Taneepanichskul S.

J Med Assoc Thai. 2008 Feb;91(2):137-41.

PMID:
18389975
19.

Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial.

Johnson JV, Lowell J, Badger GJ, Rosing J, Tchaikovski S, Cushman M.

Obstet Gynecol. 2008 Feb;111(2 Pt 1):278-84. doi: 10.1097/AOG.0b013e3181626d1b.

PMID:
18238963
20.

Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive.

Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD, Leung AT.

J Clin Pharmacol. 2007 Apr;47(4):497-509.

PMID:
17389559

Supplemental Content

Loading ...
Support Center